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Gestational trophoblastic neoplasia (GTN) comprises a spectrum of
malignant tumors derived from the trophoblast including the invasive
mole (IM), the choriocarcinoma (CH), the placental site trophoblastic
tumor (PSTT) and the epithelioid trophoblastic tumor (ETT).
PSTT is a rare entity with less than 300 cases reported and accounts
for 1–2% of GTN. Kurman et al. (1976) ﬁrst described this pathology in
1976 and named it trophoblastic pseudotumor. The malignant potential
of PSTT was recognized later, leading to the current nomenclature. It
is derived from the intermediate cytotrophoblast.
PSTT most often presents with amenorrhea or abnormal bleeding
togetherwith uterine enlargement. However, awide range of other pre-
senting symptoms has been reported such as abdominal pain, uterine
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Open access under CC BY-NC-ND licensgrowing tumor tends to stay initially in the uterus but more than 30%
of patients have metastatic disease at the time of presentation
(Schmid et al., 2009). The sites of metastases include the peritoneum,
the lung, the liver and the brain. PSTT may follow any gestational
event, normal or pathological pregnancy. In a series of 55 cases
(Baergen et al., 2006), the diagnosis was made within an interval of
34 months following a previous gestation, mainly affecting women of
childbearing age.
The prognosis of PSTT depends on the disease's extent (Schmid et
al., 2009; Baergen et al., 2006; Feltmate et al., 2001). The outcome of
patients treated for early-stage diseases is usually favorable. Hyster-
ectomy is the preferred treatment for women with localized disease.
For selected cases, partial myometrectomy may be performed to pre-
serve fertility (Saso et al., 2012). The prognosis drops rapidly when
metastatic disease is present. For advanced-stage diseases, a combi-
nation of surgery and polychemotherapy is required.
We report the case of a patient who develops a recurrence of an
ignored PSTT at the vaginal vault diagnosed 8 years after her last
pregnancy and 4 years after a hysterectomy for benign condition.Case
A 46-year-old woman, gravida 4, para 3, presented to her gynecolo-
gist complaining of abdominal pain and purulent vaginal discharge. Her
past medical history included 3 cesarean sections. The last one was
8 years prior to her presentation and a tubal ligation was performed.
Four years later, she underwent a total hysterectomy for recurrent
and infected hematocolpos in semi-urgent clinical conditions with no
further histological or radiological preoperative work-up. Histological
report showed an incomplete healing of the uterine cesarean scar and
a high-grade cervical intraepithelial neoplasia.
Clinical and ultrasound examination revealed an ovarian mass con-
sistentwith an adnexal abscess of the left ovary andan indurated vaginal
vault. Laparoscopic adnexal drainage and vaginal vault biopsy were un-
dertaken. The infectious episode resolved promptly but the vaginal biop-
sy revealed an unexpected vaginal invasive squamous cell carcinoma.
The patientwas therefore referred to a gynecologic oncologist. Clinical
examination, pelvic MRI and PET-CT identiﬁed suspicious bilateral
multilocular ovarian cysts and a 2 cm mass limited to the vaginal vaulte.
Fig. 1. A. Gross appearance of sectioned vaginal vault mass. B&C. Histological features of PSTT. Pleomorphic population of trophoblastic tumors cells focally intermixed in interstitial
ﬁbrinoid material. Note mitotic ﬁgures (C) (HE, 200×).
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vaginal lesion, bilateral salpingo-oophorectomy and pelvic lymphadenec-
tomy. The macroscopic examination of the vaginal tumor reveals an
ill-deﬁned nodular growth measuring 3.5 × 3.5 × 3.8 cm. The mass is
pearly white color with areas of hemorrhage (Fig. 1, A). On microscopic
examination, the tumor consists of a pleomorphic population of polygo-
nal intermediate trophoblast cells with amphophilic to clear cytoplasm.
These cells have often a single irregular highly atypical nucleuswith focal-
ly prominent nucleoli, but some are multinucleate, resembling to
syncytiotrophoblastic giant cells (Fig. 1, B&C). Mitotic ﬁgures (2/10 high
power ﬁeld), extensive necrosis, hemorrhage and vascular invasion are
observed. The immunohistochemical pattern is ambiguous (Fig. 2). The
staining of hCG, hPL and inhibine is only focally positivewhile the staining
of placental alkaline phosphatase (PLAP) is more diffuse. The staining of
CKAE1/AE3 and CK7 is positive and the staining of CK5/6 and P63 is neg-
ative. The staining of CD30 and alpha-fetoprotein (AFP) is also negative.
Finally, Ki-67 is expressed in 60–70% of the tumor cells. The pathological
diagnosis of PSTT is proposed and conﬁrmed by the expert panel of pa-
thologists of the Belgian Referent Center of GTD. The oophorectomy and
the lymph node status are negative. In this context, the pathology slides
of the hysterectomy performed 4 years previously were reviewed and
showed no sign of PSTT.
The serum hCG concentration was elevated to 41.0 UI/L the day
after the surgery. Serum hPL level was not measured. An extended ra-
diological work-up did not show evidence of metastasis.
Treatment options including adjuvant chemotherapy versus obser-
vation were discussed. Considering that surgery remains the preferred
treatment for patients with localized PSTT, that total surgical resection
of the unique lesion was achieved and that PSTT tends to be resistant
to chemotherapy, observation has been elected. After a follow-up of
10 months, the patient is still in clinical, biological (β-hCG) and radio-
logical (pelvic MRI) remission.
Discussion
As shown in this case report, clinical and pathological presentation
of PSTT can be extremely variable. It can be challenging to distinguish
PSTT from other forms of GTN or nontrophoblastic tumors. The dis-
tinction is critical because behavior, staging system and management
are different. The review of the pathology by experts in this ﬁeld is ofFig. 2. Immunophenotype of tumor cells (HIS, 100×). A, B & C. The staining of hCG (A) and hP
hPL is usually strong and diffuse while expression of PLAP is negative or focal.paramount importance as demonstrated by the experience from sev-
eral European referral centers.
Laboratory examinations can be helpful to conﬁrm the diagnosis.
In contrast to other forms of GTN, PSTT arises from the
implantation-site intermediate trophoblast. Given that hCG is produced
by syncytiotrophoblasts, the serum hCG levels in PSTT do not correlate
with the tumor burden neither with the malignant behavior and thus
have no predictive value (Hassadia et al., 2005). By contrast, the hPL
level is elevated in most cases. Furthermore, the hCG-free ß-subunit is
the main form of hCG in PSTT, as reported recently by Cole et al., and
could be used to distinguish PSTT from other trophoblastic neoplasia
and nontrophoblastic tumors that produce hCG (Cole et al., 2006).
Immunochemistry is a useful diagnostic method. The classical
immunophenotypic pattern of PSTT in comparison of choriocarcinoma
and nontrophoblastic tumor is illustrated in Table 1 (Mazur, 2005). How-
ever, as observed in the present case, there is some overlapping between
diagnostic criteria for PSTT and choriocarcinoma.
Information about optimal management strategy is restricted be-
cause the condition is rare and the natural course varies widely. The
revised 2000 FIGO staging system (Oncology, 2002) has a prognostic
and therapeutic usefulness for GTN. PSTT should be considered sepa-
rately. Indeed, studies show that prognostic factors of the GTN staging
system do not apply accurately to PSTT. The FIGO anatomical staging
system is the strongest predictor of patient outcome presenting with
PSTT (Schmid et al., 2009; Baergen et al., 2006). A retrospective re-
view of 62 patients with PSTT treated over a 30-year period indicates
that the probability of 10-year overall survival for those with stage I, II
or III/IV disease was respectively 90, 52 and 49%. This further supports
the importance of an early diagnosis (Schmid et al., 2009). Other fac-
tors associated with an unfavorable outcome include patient's age
(older than 35 years), prolonged intervals from previous pregnancy
(over 48 months), prior term pregnancy, high hCG level (over
1000 mIU/ml), tumor size, depth ofmyometrial invasion, tumor necrosis,
highmitotic count (over 5 per 10 HPF) and clear cytoplasm. It is interest-
ing to note that the prognostic factors are derived from pathological anal-
ysis of the uterus and therefore are not fully applicable for the present
case. Management of recurrence is generally based on data derived
from metastatic disease treatment. Schmid et al. (2009) report that the
prognosis of patients developing recurrent or refractory disease is poor
and that only four (22%) patients achieved long-term survival beyondL (B) is focally positive. The staining of PLAP (C) is more diffuse. In PSTT, the staining of
Table 1
Characteristic immunohistochemical proﬁles of PSTT, choriocarcinoma and
nontrophoblastic tumors.
PSTT Choriocarcinoma Nontrophoblastic tumor
hCG +/− +++ +/−
hPL +++ + −
PLAP − +/− +/−
Inhinin-α ++ ++ −
Mel-CAM (CD 146) +++ ++ −
CK AE1/3, CK 18 +++ +++ +++a
EMA ++ + ++a
P63 − + +
Ki67b 10–30% >50% Variable
Mel-CAM : Melanoma cell adhesion molecule; CK : Cytokeratine; EMA : epithelial
membrane antigen.
a CK and EMA only immunostaining for carcinomas.
b Marker of proliferative activity.
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agement of local recurrence are limited.
Authors propose a stage-adaptedmanagement. Surgery is advocated
for stage I disease. They recommend adjuvant chemotherapy for patients
who have risk factors of recurrence or persistent raised postoperative
serum hCG level or both. Patients with stage II, III or IV PSTT are usually
managed with combined surgery and chemotherapy. There is no deﬁni-
tive evidence of beneﬁt of adjuvant chemotherapy for stage II disease.
Given that PSTT is less chemotherapy responsive than other types of
GTN, polychemotherapy is recommended. Although there is no conclu-
sive difference between platinum-based versus non-platinumbased reg-
imens, a platinum-containing multidrug chemotherapy is generally
preferred such as EP/EMA (Schmid et al., 2009).Conclusion
The relevance of this case lies in its atypical clinical and patholog-
ical presentation. Gynecologists confronted with vaginal lesion must
consider besides primary vaginal tumors, secondary vaginal implants
even if the patient underwent a hysterectomy. Indeed, 84% of vaginal
cancers are metastases and arise not only from GTN but also from
other gynecologic malignancies, melanoma, hypernephroma, bladder
cancer, breast cancer and colorectal adenocarcinoma.Any gynecologist who has to deal with PSTT faces a challenge not
only in terms of diagnosis but also in terms of therapy. Although sev-
eral authors try to establish management strategy, a management al-
gorithm remains controversial because of the lack of data due to the
low incidence of the disease and its unpredictable course. Patients
should ideally be referred to a center with expertise in gestational
trophoblastic disease to assure their optimal care.
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